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Abstract
Hepatorenal syndrome (HRS) is a manifestation of ex-
treme circulatory dysfunction and entails high morbidity 
and mortality. A new definition has been recently 
recommended by the International Club of Ascites, accor-
ding to which HRS diagnosis relies in serum creatinine 
changes instead that on a fixed high value. Moreover, 
new data on urinary biomarkers has been recently 
published. In this sense, the use of urinary neutrophil 
gelatinase-associated lipocalin seems useful to identify 
patients with acute tubular necrosis and should be 
employed in the diagnostic algorithm. Treatment with 
terlipressin and albumin is the current standard of 
care. Recent data show that terlipressin in intravenous 
continuous infusion is better tolerated than intravenous 
boluses and has the same efficacy. Terlipressin is 
effective in reversing HRS in only 40%-50% of patients. 
Serum bilirubin and creatinine levels along with the 
increase in blood pressure and the presence of systemic 
inflammatory response syndrome have been identified 
as predictors of response. Clearly, there is a need for 
further research in novel treatments. Other treatments 
have been assessed such as noradrenaline, dopamine, 
transjugular intrahepatic portosystemic shunt, renal 
and liver replacement therapy, etc . Among all of them, 
liver transplant is the only curative option and should be 
considered in all patients. HRS can be prevented with 
volume expansion with albumin during spontaneous 
bacterial peritonitis and after post large volume para-
centesis, and with antibiotic prophylaxis in patients 
with advanced cirrhosis and low proteins in the ascitic 
fluid. This manuscript reviews the recent advances in 
the diagnosis and management of this life-threatening 
condition.
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Core tip: Hepatorenal syndrome (HRS) is a life-threa-
tening complication present in very advanced liver 
cirrhosis. This manuscript addresses many recent 
advances in this field, including the recent change in 
the definition of HRS according to acute kidney injury 
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criteria, the potential consequences of the adoption of 
this new definition, and the use of biomarkers to help 
in the diagnostic algorithm. Moreover, it reviews the 
recent advances in treatment of HRS such as the use of 
continuous infusion of terlipressin instead of bolus and 
the low efficacy of midodrine plus octreotide. Potential 
areas of research are identified as well.
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INTRODUCTION
Hepatorenal syndrome (HRS) is a manifestation of 
extreme circulatory dysfunction. It develops in the setting 
of advance stage in cirrhosis and carries an ominous 
prognosis.
HRS is diagnosed clinically. Its definition has been 
updated recently in accordance with the acute kidney 
injury (AKI) criteria. 
Current standard of care involves the use of vasocon­
strictor therapy (i.e., terlipressin) and volume expansion 
with albumin. Treatment is effective in only 40%­50% 
of cases and it recurs in up to 50% of those cases re­
sponding to treatment. Liver transplant (LT) should be 
considered in all patients without contraindications for it.
Areas of research would be aimed at improving the 
accuracy of diagnosis of HRS, identifying predictors of 
non­response, and testing novel treatments.
PATHOPHYSIOLOGY
HRS is caused by extreme circulatory dysfunction. 
Hepatocytes and stellate cells in a cirrhotic liver produce 
numerous local acting vasodilators such as nitric oxide, 
cannabinoids, etc. These vasodilators act locally on 
the splanchnic circulation producing splanchnic arterial 
vasodilation. Splanchnic circulation represents an impor­
tant part of the circulation of the body. Thus, splanchnic 
vasodilation produces a decrease in mean arterial pre­
ssure (MAP), which in turn triggers the activation of the 
sympathetic nervous system, leading to high levels of 
circulating noradrenaline, which along with an increase in 
cardiac output are the early mechanisms compensating 
circulatory dysfunction during this early stage and keep 
MAP stable[1].
As the disease progresses and splanchnic vaso­
dilation gets worse other vasoconstrictor systems get 
activated such as the renin­angiotensin­aldosterone 
system and vasopressin release[1]. 
Aldosterone enhances retention of sodium and water 
by the kidneys leading to development of ascites. Vaso­
pressin enhances retention of free water conducting to 
hyponatremia. The splanchnic vascular bed is refractory 
to the action of all these vasoconstrictor systems which 
on the contrary act effectively on other vascular beds 
such as the femoral and brachial vessels (producing 
cramps), in vessels in the brain (potentially playing a 
role in encephalopathy) and in the renal arteries (leading 
to HRS)[1,2]. In this sense, mean renal artery resistive 
index increases gradually from patients with cirrhosis but 
no ascites, in those with ascites, refractory ascites and 
HRS[3,4].
Therefore, HRS is a functional disease characterised 
by marked vasoconstriction of the renal arteries secondary 
to the effect of hyper­activation of different vasoconstrictor 
systems aimed at compensating the systemic vasodilation 
caused by the initial splanchnic vasodilation. HRS always 
develops in the setting of advance circulatory dysfunction 
and it is always accompanied by ascites and usually by 
hyponatremia[1].
HRS can develop in the setting of infection, mainly 
after spontaneous bacterial peritonitis (SBP), as a conse­
quence of a worsening degree of circulatory dysfunction 
caused by sepsis. Volume expansion with albumin 
prevents effectively development of HRS in patients with 
SBP[5].
HRS can also develop in the setting of circulatory 
dysfunction after large volume paracentesis (LVP). This 
complication is prevented by replacing albumin after 
LVP[6]. 
DIAGNOSIS OF HRS ACCORDING TO 
THE NEW DEFINITION OF AKI
Classically, acute renal failure in cirrhosis was defined as 
an increase in serum creatinine (sCr) levels of ≥ 50% 
from baseline to a final level above 1.5 mg/dL (133 
µmol/L), and classical definition of HRS type-1 was doubling 
sCr levels over 2.5 mg/dL or 220 µmol/L within 2 wk. 
Serum creatinine overestimates renal function in cirrhotic 
patients due to a number of factors: Creatinine production 
in patients with cirrhosis is reduced due to muscle wasting, 
there is an increased secretion of creatinine in the renal 
tubules, sCr may be diluted due to an increased volume of 
distribution, and finally, high bilirubin levels may interfere 
with the assays to measure accurately its level. Recently, 
the International Club of Ascites (ICA) has adopted the 
concept of AKI which was developed originally to be 
used in general critically­ill patients. AKI is defined as 
the increase of at least 0.3 mg/dL (26 µmol/L) and/or ≥ 
50% from baseline, within 48 h[7].
Diagnostic criteria of HRS according to ICA­AKI criteria 
are the following[7]: (1) diagnosis of cirrhosis and ascites; 
(2) diagnosis of AKI according to ICA­AKI criteria; (3) no 
response after 2 consecutive days of diuretic withdrawal 
and plasma volume expansion with albumin (1 g/kg 
of body weight); (4) absence of shock; (5) no current 
or recent use of nephrotoxic drugs (non­steroidal anti­
inflammatory drugs, aminoglycosides, iodinated contrast 
media, etc.); and (6) no macroscopic signs of structural 
kidney injury, defined as absence of proteinuria (> 500 
mg/d), absence of microhematuria (> 50 red blood 
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cells per high power field) and normal findings on renal 
ultrasound.
The main change produced by adopting the new 
definition of HRS is the removal of a rigid very high 
cut­off value of sCr (2.5 mg/dL or 220 µmol/L) to start 
pharmacologic treatment. In this way, treatment can be 
administered early and potentially better efficacy could 
be achieved.
However, these clinical criteria do not allow differen­
tiation between HRS and parenchymal renal disease, 
which is extremely important because vasoconstrictors 
will not be effective and could even worsen the renal 
dysfunction. Thus, there is a wide interest in developing 
urinary biomarkers to help in the differential diagnosis of 
HRS.
URINARY BIOMARKERS IN AKI
Currently, numerous biomarkers have been assessed in 
the setting of AKI and liver cirrhosis including neutrophil 
gelatinase­associated lipocalin (NGAL), interleukin­18, 
liver­type fatty acid binding protein (L­FABP), kidney injury 
molecule­1, toll­like receptor 4, π­glutathione S­transferase 
and α­glutathione S­transferase[8]. Among all of them, 
current data show that NGAL is the most useful marker. 
NGAL detects patients with acute tubular necrosis (ATN). 
On the contrary, NGAL is not helpful to differentiate 
between pre­renal azotemia and HRS. NGAL urinary 
levels are much higher in patients with ATN compared to 
patients with other causes of AKI. Urinary levels of NGAL 
in ATN were 417 µg/L, compared with levels at 30 µg/L in 
pre­renal azotemia, 82 µg/L in chronic kidney disease and 
76 µg/L in HRS, P < 0.001[9,10]. Thus, incorporating NGAL 
into the clinical decision algorithm would be of benefit to 
rule out structural kidney injury and detecting a group 
of patients in whom treatment with vasoconstrictors 
wouldn’t be effective and only would produce potentially 
serious side effects[11].
CURRENT TREATMENT (STANDARD OF 
CARE)
Once patients with AKI have received volume expansion 
with albumin (1 g per kilogram) with no response achieved 
in the following 48 h, and criteria of HRS are fulfilled, then 
treatment with terlipressin is recommended. Expansion 
with albumin should be continued at the dose of 20­40 g 
daily.
Response to treatment should be assessed regularly 
and terlipressin should be titrated gradually up to a 
maximum dose of 12 mg per day. Terlipressin should be 
used for a maximum of 14 d and stopped in case of lack 
of response[7].
Response is defined as a reduction of at least 25% 
from baseline sCr level, that is from sCr level before 
treatment with terlipressin was started[7].
Response is achieved in around 40%­50% of patients. 
The rate of recurrence of HRS is 30%. A definitive treat-
ment of the circulatory dysfunction and the underlying liver 
cirrhosis with liver transplantation should be considered 
in all cases with no contraindications. Otherwise, the 
persistent advanced circulatory dysfunction makes HRS 
recur frequently and predispose the patient to other major 
decompensations[12]. This is the rationale supporting 
prioritization of patients with HRS on the waiting list for 
LT in some centres. Terlipressin and albumin is not a 
definitive treatment but should be considered as a bridge 
to a definitive treatment, i.e., LT. 
Two randomized studies showed that HRS reversal 
rate when terlipressin plus albumin was employed was 
higher compared to the reversal achieved employing 
albumin alone. Martín­Llahí et al[13] reported a much 
higher rate of improvement in renal function in patients 
treated with terlipressin and albumin compared to those 
patients treated only with albumin (43.5% vs 8.7%, P 
= 0.017). This result may be influenced by the fact that 
patients who did not tolerate terlipressin were excluded 
from the analysis. Sanyal et al[14] also showed that HRS 
reversal was achieved more frequently in those patients 
treated with terlipressin and albumin compared with 
those treated only with albumin (33.9% vs 12.5%, P = 
0.008). Any of these studies showed difference in survival 
at 3­mo and 6­mo. A large randomized trial has been 
published recently and it showed a higher rate of HRS 
reversal in those patients receiving terlipressin (23.7% vs 
15.2%, P = 0.13). This difference did not reach statistical 
significance, probably due to the fact that one third of 
patients received fewer than three days of treatment, 
which could affect the effectiveness of the treatment. 
When the analyses were done stratifying patients by 
the degree of reduction in serum creatinine level, data 
showed that a decrease in sCr level, even if not reaching 
a complete reversal, has a positive impact on survival[15].
Traditionally, terlipressin has been used in bolus 0.5­1.0 
mg every 4­6 h. Recent data show that continuous 
infusion of terlipressin has the same efficacy compared 
with bolus administration and it is better tolerated pre­
senting fewer side effects (35.29% vs 62.16%, P < 
0.025). Probably, side effects were lower because the total 
effective daily dose required was lower in the infusion 
groups compared to the bolus group (2.23 ± 0.65 mg/d 
vs 3.51 ± 1.77 mg/d, P < 0.05)[16]. 
Therefore, we recommend employing terlipressin at 
2 mg per day in continuous infusion (diluted in 250 mL 
of Dextrose 5%) along with albumin (20­40 g per day). 
Response should be assessed every 48 h. If response 
is not achieved in 48 h, then terlipressin dose should be 
increased in a stepwise manner (increase in 2 mg per 
day).
These patients need careful observation, including 
review of ischaemic side effects on acral parts, ischaemic 
heart events, bowel ischaemia (diarrhoea). They can also 
develop hyponatremia and arrhythmias.
PREDICTORS OF RESPONSE TO 
TERLIPRESSIN AND ALBUMIN
There are only few published studies assessing pre­
Acevedo JG et al . Hepatorenal syndrome
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dictors of response to treatment in HRS. These studies 
show there is a close relationship between effective­
ness of treatment and capacity to improve systemic 
hemodynamics. Patients in whom terlipressin did not 
increase the MAP in at least 5 mmHg at day 3 of treat­
ment had a lower rate of response. Effectiveness of 
treatment is also related with degree of liver dysfunction. 
Those patients who did not increase MAP at day 3 and 
who also had high baseline bilirubin levels ≥ 171 µmol/L 
(10 mg/dL) had a poor response rate, of only 9%[17]. 
Another study showed that baseline creatinine levels 
predicted HRS reversal, suggesting that early intervention 
would be more effective[18]. A recent retrospective study 
showed that those patients with systemic inflammatory 
response syndrome (SIRS) had a much higher response 
rate to terlipressin (42.9% vs 6.7%, P = 0.018), while 
terlipressin did not show more efficacy than placebo 
when employed in patients without SIRS (15.9% vs 
18.8%, P = NS)[19]. 
A recent abstract showed that no response to treat­
ment was associated with higher urinary NGAL levels 
(728.8 µg/L vs 182.9 µg/L, P = 0.02), probably related to 
the presence of acute tubular necrosis in those patients[20].
In summary, the following markers to predict re­
sponse to treatment (terlipressin) have been identified: 
Low baseline creatinine and bilirubin levels, increase in 
blood pressure, presence of SIRS and low urinary NGAL.
OTHER TREATMENTS
LT
Patients with HRS type­1 with no contraindications for a LT 
should be invariably worked up and place in the LT waiting 
list because LT is the only definitive treatment for HRS. 
LT reverses liver dysfunction and portal hypertension. 
Patients with HRS have worse survival expectancy than 
other patients with cirrhosis for any given value of MELD 
score, which suggests HRS is a factor of poor prognosis 
independently from MELD score[21,22]. Furthermore, there 
is evidence that structural injury to the renal tubules 
occur early in the course of HRS­1 and the longer the 
patient is awaiting the transplant and suffering from HRS 
the higher the risk of not recovering their renal function 
or even requiring a renal transplant after LT[23]. In this 
sense, experts recommend to prioritize these patients by 
using pre­treatment levels of creatinine or considering 
the pharmacological treatment of HRS as haemodialysis 
when calculating MELD score[24]. Currently, there is no 
general consensus about prioritization of patients with HRS 
awaiting a LT. Some centres prioritize these patients and 
some others don’t. The major challenge LT programmes 
face is the shortage of donors and consequently op­
timization in the allocation of the few organs available 
becomes extremely necessary. Thus, we suggest that 
those patients with recurrent episodes of HRS­1, hence 
at high risk of developing refractory HRS, are at high 
risk of dropping out of the LT waiting list or at risk of not 
recovering their renal function after LT, and therefore will 
get most benefit from early transplantation. 
Midodrine and octreotide
Combination of midodrine and octreotide (MID/OCT) plus 
albumin is widely used in countries where terlipressin is 
not available. A recent randomized trial showed a much 
lower response rate in patients treated with MID/OCT 
compared to patients treated with terlipressin (4.8% 
vs 55.6%, P < 0.01). Three­month survival rate, after 
exclusion of patients who received rescue treatment, 
was also lower in the MID/OCT group (29% vs 56%, P = 
0.06)[25]. These data show midodrine in combination with 
octreotide is not an effective treatment for HRS.
Noradrenaline
A recent randomized study comparing noradrenaline with 
terlipressin showed HRS reversal is achieved in 43.4%, 
similar to the reversal rate achieved with terlipressin 
(39.1%). Survival at 15 d of therapy was similar in the 
noradrenaline and terlipressin group (39.1% vs 47.8%, 
P = 0.461)[26]. A recent meta­analysis analysed 4 studies 
including 152 patients and suggested that treatment with 
noradrenaline is as effective as terlipressin in reversing 
HRS when used along with albumin[27]. Therefore, nora­
drenaline is an effective therapy for HRS. Noradrenaline 
main drawback is that its use generally requires an 
intensive care unit setting.
Dopamine
Low-dose dopamine increases renal blood flow but shows 
no effect on glomerular filtration rate or on the outcome 
in HRS. In a recent study, dopamine didn’t show reduc­
tion of creatinine levels after 5 d of treatment[28,29]. It is 
not considered an appropriate treatment for HRS.
Transjugular intrahepatic portosystemic shunt 
HRS type­1 usually occurs in the setting of advanced liver 
dysfunction and transjugular intrahepatic portosystemic 
shunt (TIPS) is usually contraindicated on this basis. 
There are few small trials showing improvement on renal 
function and deactivation of vasoconstrictor system, 
i.e., reduction in levels of renin, aldosterone and nora­
drenaline after TIPS insertion[30,31]. However, data is very 
limited to recommend its use in clinical practice.
Renal and liver replacement therapy
Haemodialysis is employed in those patients awaiting 
LT whose renal function failed to respond to medical 
treatment and at the same time bring the extra points 
required for prioritization. 
Liver support with molecular adsorbent recirculating 
system (MARS) has been tested in small cohorts of 
patients who did not respond to vasoconstrictors and had 
advanced liver dysfunction, which usually precludes TIPS 
insertion. One trial showed the reduction in creatinine 
and bilirubin levels was higher in the MARS group com­
pared with the continuous haemodialysis group[32]. 
Another study showed no significant changes in systemic 
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haemodynamics and glomerular filtration rates following 
MARS treatment[33]. Treatments employed at this stage 
should be restricted to patients awaiting a definitive 
treatment (i.e., LT). It would be controversial to employ 
such invasive treatments in patients with contraindication 
for LT, and thus with no option for a definitive treatment. 
Serelaxin
Serelaxin is a recombinant form of the human peptide 
hormone relaxin­2, increases renal perfusion in healthy 
human volunteers. Its properties have been explored 
in a pilot study on compensated cirrhotic patients and 
it showed increase renal blood flow by 65.4% from 
baseline with no effect on systemic blood pressure[34]. 
Data on this hormone is still scarce.
PREVENTION
HRS can be prevented in different clinical scenarios. 
The first one is in the setting of SBP. The deleterious 
effect on circulatory dysfunction produced by SBP can 
be prevented by volume expansion with albumin. The 
pioneer study of the Barcelona group showed that those 
patients receiving albumin prevented development of 
renal failure (10% vs 33%, P = 0.002) and reduced short­
term mortality (mortality at 3­mo, 22% vs 41%, P = 
0.03)[9]. There are still no convincing data to recommend 
plasmatic expansion with albumin in patients with other 
types of infections different from SBP. One trial showed a 
tendency to develop renal failure less frequently in those 
patients without renal failure at baseline and receiving 
expansion with albumin (3% vs 10%, P = NS)[35].
HRS can be prevented after LVP, albumin at a dose 
of 6­8 g per litre of ascites removed is the dose most 
commonly used to prevent worsening of circulatory 
dysfunction, and thus minimize the impact on electrolytes, 
creatinine and renin levels. Volume expansion with 
albumin also improves survival after LVP and it is recom­
mended by international societies[36,37].
HRS can also be prevented with primary antibiotic 
prophylaxis of SBP. Fernández et al[38] showed in a cohort 
of patients with advanced cirrhosis that SBP primary 
prophylaxis reduced development of HRS (28% vs 41%, P 
= 0.02) and mortality at 3 mo (94% vs 62%, P = 0.003), 
this effect is probably related to the effect of Norfloxacin 
in reducing the levels of bacterial products within the gut 
and hence reducing bacterial translocation.
AREAS FOR FUTURE RESEARCH 
Definition of HRS is continuously changing and it is based 
on clinical grounds, relying on serum creatinine levels, 
which has many limitations as marker of renal function. 
Research focused on new biomarkers, such as urinary 
NGAL, to make the diagnostic algorithm of HRS more 
accurate is clearly needed and fortunately, interest in this 
field is increasing.
Moreover, identifying patients with low probability of 
responding to treatment is of major importance in order 
to start early alternative treatments and potentially 
prioritize these patients on the LT waiting list.
Finally, research looking for novel treatments besides 
intravenous terlipressin and expansion with albumin is 
also needed.
CONCLUSION
HRS is a major decompensation in advanced liver cirrhosis. 
It entails a high short-term mortality rate. Current definition 
is based on clinical grounds and has been recently modified 
adopting AKI definition. Recent data on urinary NGAL 
show it is useful to differentiate acute tubular necrosis 
and should be incorporated in the diagnostic algorithm of 
HRS. Terlipressin and noradrenaline are the only effective 
treatment currently available and reversal rate is only 
40%­50% of cases. Data on predictors of response to 
treatment suggest that treatment should be started as 
early as possible. In this sense, ICA new definition of 
HRS allows an early diagnosis. New treatments should 
be tested for this life­threatening condition. Finally, LT 
is the only curative treatment and should be always 
considered.
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